In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 22246-12-4, name is 6-Methoxy-3,4-dihydroisoquinolin-1(2H)-one, introducing its new discovery. Quality Control of 6-Methoxy-3,4-dihydroisoquinolin-1(2H)-one
A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and – CHR3- is =CH- linked by the double bond to cyclopentanone; or – (-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR’, CN, COR, CF3, SOR, SO2R, SONRR’, SO2NRR’, NO2, halogen, heteroaryl; and the pharmaceutical salts and stereisomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer’s disease.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 22246-12-4, and how the biochemistry of the body works.Quality Control of 6-Methoxy-3,4-dihydroisoquinolin-1(2H)-one
Reference：
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem